Precision Medicine in Colorectal Cancer: Harnessing the Power of MRD Surveillance and Emerging Guidelines

Join OncoDaily, in partnership with Natera, for an expert-led webinar focusing on the rapid advancement of personalized monitoring and treatment strategies in colorectal cancer (CRC).

The clinical management of colorectal cancer is undergoing a major evolution with the integration of circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing. Presented in collaboration with Natera, this session features Dr. Rob Lentz reviewing how longitudinal ctDNA surveillance transforms routine post-operative care and adjuvant treatment decisions.

Attendees will explore the newest clinical evidence, updated consensus guidelines, and real-world data demonstrating how serial ctDNA monitoring helps identify recurrence months ahead of standard imaging. The presentation will also delve into actionable decision-making frameworks, including treatment escalation or de-escalation in the adjuvant setting and emerging neoadjuvant immunotherapy combinations.

Date: November 13, 12:00 PM PT (Noon PT)
Live Platform: X (OncoDaily)
Presenster: Rob Lentz (Medical Director for GI Oncology at Natera)
Host: Mariam Khachatryan  (OncoDaily)

Who Should Attend

This session is designed for medical oncologists, surgical oncologists, gastrointestinal specialists, clinical pathologists, and healthcare providers involved in the multidisciplinary management of colorectal cancer.